Juan Carlos Rejon-Parrilla
Overview
Explore the profile of Juan Carlos Rejon-Parrilla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rejon-Parrilla J, Epstein D, Perez-Troncoso D, Espin J
Health Econ Policy Law
. 2025 Jan;
:1-18.
PMID: 39881538
Although the criteria that support reimbursement decisions for medicines are often set by legislation, as is the case in Spain, in many cases neither the definition nor the measurement methods...
2.
Aranda J, Dobrzynska A, Rosario-Lozano M, Rejon-Parrilla J, Epstein D, Blasco-Amaro J
Expert Rev Pharmacoecon Outcomes Res
. 2024 Dec;
:1-15.
PMID: 39618103
Introduction: The new European Medical Device Regulation has raised the bar for the clinical evaluation of medical devices to gain marketing authorization by Notified Bodies (NBs) regarding certificates of conformity...
3.
Ritore A, Jimenez C, Gonzalez J, Rejon-Parrilla J, Hervas P, Toro E, et al.
PLOS Digit Health
. 2024 Sep;
3(9):e0000599.
PMID: 39283912
No abstract available.
4.
Rejon-Parrilla J, Espin J, Garner S, Kniazkov S, Epstein D
Front Pharmacol
. 2023 Dec;
14:1199500.
PMID: 38089054
Advanced Therapy Medicinal Products are a type of therapies that, in some cases, hold great potential for patients without an effective current therapeutic approach but they also present multiple challenges...
5.
Brazier J, Peasgood T, Mukuria C, Marten O, Kreimeier S, Luo N, et al.
Value Health
. 2022 Mar;
25(4):482-491.
PMID: 35277337
Objectives: Existing measures for estimating quality-adjusted life-years are mostly limited to health-related quality of life. This article presents an overview of the development the EQ-HWB (EQ Health and Wellbeing), which...
6.
Rejon-Parrilla J, Espin J, Epstein D
Health Econ Rev
. 2022 Jan;
12(1):1.
PMID: 34981266
Background: What constitutes innovation in health technologies can be defined and measured in a number of ways and it has been widely researched and published about. However, while many countries...
7.
Kent S, Salcher-Konrad M, Boccia S, Bouvy J, de Waure C, Espin J, et al.
J Comp Eff Res
. 2021 Jul;
10(14):1035-1043.
PMID: 34279114
Health technology assessment (HTA) is increasingly informed by nonrandomized studies, but there is limited guidance from HTA bodies on expectations around evidence quality and study conduct. We developed recommendations to...
8.
Peasgood T, Mukuria C, Carlton J, Connell J, Devlin N, Jones K, et al.
Eur J Health Econ
. 2021 Apr;
22(7):1067-1081.
PMID: 33909157
Economic evaluation combines costs and benefits to support decision-making when assessing new interventions using preference-based measures to measure and value benefits in health or health-related quality of life. These health-focused...
9.
Rejon-Parrilla J, Jonsson P, Bouvy J
Br J Clin Pharmacol
. 2019 Mar;
85(7):1427-1433.
PMID: 30849187
In 2016, the European Medicines Agency published the conclusions of its pilot on adaptive pathways, with products in early stages of development still building up to their marketing authorisation. Adaptive...
10.
Peel A, Jenks M, Choudhury M, Lovett R, Rejon-Parrilla J, Sims A, et al.
Appl Health Econ Health Policy
. 2019 Feb;
17(2):263-264.
PMID: 30746616
In Sect. 3.3.1, the second sentence of the second paragraph.